— Accelerating Global Healthcare and Human–AI Interaction via Biological Data Analysis Powered by Integrated AI & BCI*1 Technologies —

*1: BCI (Brain-Computer Interface: Interface technology that directly connects the brain and computers to exchange information through interpretation by AI and other analytics)

Bio Search Co., Ltd. (Headquarters: Chuo-ku, Tokyo; President and CEO: Takahiro Omuro; hereinafter “Bio Search”), a developer and provider of biological sensing devices, medical equipment, and data analysis platforms, has executed a Share Exchange Agreement to acquire 100% of the shares of InnerEye Ltd. (Headquarters: Herzliya, Israel; CEO: Uri Antman; hereinafter “InnerEye”), a deep-tech company renowned for its real-time electroencephalogram (EEG) analysis and Brain-AI (brain-inspired artificial intelligence) technologies, making InnerEye a wholly owned subsidiary.

(Note: Closing of this transaction is subject to the satisfaction of customary conditions precedent, including regulatory approvals from relevant Israeli authorities, and is scheduled to take place between December 2026 and early January 2027.)

1. Background and Purpose: Uniting Bio Search’s Business Foundation with World-Class Academic Technology

Bio Search provides healthcare AI solutions utilizing biological signals such as EEG, ECG, heart rate, and EMG. Our core strengths lie in biological sensing technologies, medical device engineering know-how, and extensive business development capabilities across Japan and Asian markets.

InnerEye is a deep-tech Brain-AI company founded upon breakthroughs from the Hebrew University of Jerusalem—internationally celebrated for its brain and cognitive science research—and Ben-Gurion University of the Negev, acclaimed for its advanced engineering. InnerEye possesses proprietary algorithms capable of analyzing human EEG signals in real time, identifying cognitive states associated with perception and decision-making with high precision.

By combining Bio Search’s biological sensing capabilities, medical device design expertise, and foriegn market presence with InnerEye’s cutting-edge Brain-AI technology, we aim to become a global leader and sole platformer in next-generation medical care, brain-tech, and advanced cognitive AI interaction, across healthcare, industry, and security.

2. Key Synergies and Future Outlook

• Exponential Improvement in AI Accuracy via Algorithm & Data Integration:

By pooling and training on biological and EEG data (Bio-Intelligence) across both companies within a unified platform, we will dramatically expand our AI models’ precision, robustness, and analytical scope.

• Dominance in Healthcare, Advanced Medicine, Human–AI Interaction, and Industrial Applications:

In addition to visualizing cognitive functions and supporting early diagnostics in medical/healthcare fields, we will rapidly address massive, growing global markets (TAM), including industrial automation, affective computing, security, and expert decision support.

• Establishment of a Global Management Structure and Roadmap Toward a 2028 NASDAQ Listing:

We will establish a unified executive management structure (such as a Management Committee) spanning Japan and Israel. While reinforcing corporate governance and internal controls, we will accelerate business growth targeted toward a NASDAQ listing in 2028.

[InnerEye Overview]

• Company Name: InnerEye Ltd.
• Headquarters: Herzliya, Israel
• Representative: Uri Antman, CEO
• Establishment: 2014
• Company Profile:

InnerEye was co-founded by Professor Amir Geva (Professor of Electrical & Computer Engineering at Ben-Gurion University) and Professor Leon Deouell (Medical Doctor, and Professor of Brain Sciences at The Hebrew University of Jerusalem). Building upon and combining their research and expertise, InnerEye became the first in the world to materialize and productize technology that captures brain states via EEG, learns the unique cognitive and decision-making processes shaped by individual experience and tacit knowledge, and deploys these trained models into operation.

InnerEye’s technology bridges the gap where conventional AI struggles—interpreting complex human tacit knowledge directly through brain activity—enabling advanced expert-level automation, real-time operator assistance, and accelerated professional training.

• Website: https://www.innereye.ai/

3. Comments from Company Representatives

■ Takahiro Omuro, President & CEO, Bio Search Co., Ltd.

“We wholeheartedly welcome the InnerEye team, who possess world-class EEG analysis and AI technology, to our group. By unifying our cutting-edge technologies and business development capabilities, we create a one-of-a-kind platform that will pioneer the future of brain science, healthcare, and human potential. We are committed to meeting the expectations of our shareholders and investors as we maximize enterprise value on the global stage.”

■ Uri Antman, CEO, InnerEye Ltd.

“Joining forces with Bio Search is the ideal partnership to elevate the Brain-AI technology we have cultivated over many years into a global commercial scale. By integrating our mutual strengths, we look forward to enhancing the quality of life for people worldwide and contributing to a safer, more productive and adaptive society.”

(End of Press Release)